Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...